Communiqués Kamada Ltd.

Actions

KMDA

IL0010941198

Produits pharmaceutiques

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 12:44:50 19/06/2026			Varia. 5j.	Varia. 1 janv.
2 119,00 ^ILa	-0,89%		-2,57%	-6,24%

01/06	Kamada annonce l'agrément de la FDA pour son nouveau laboratoire interne de tests de neutralisation du virus de la rage	CI
13/05	Transcript : Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026

Communiqués

01/06	Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory	AQ
13/05	Kamada: Q1 Earnings Snapshot	AQ
13/05	Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year	AQ
06/05	Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026	AQ
31/03	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders	AQ
26/03	Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas	AQ
11/03	Kamada : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)	PU
11/03	Kamada: Q4 Earnings Snapshot	AQ
11/03	Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth	AQ
11/03	Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy	AQ
04/03	Will release financial results for the Fourth quarter 2025, on March 11, 2026, and will host conference call 8:30am ET	PU
04/03	Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026	AQ
13/01	Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio	EQ
07/01	Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance	AQ
18/12	Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender	AQ
08/12	Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026	AQ
18/11	Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year	EQ
10/11	Kamada: Q3 Earnings Snapshot	AQ
10/11	Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth	AQ
04/11	Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation	AQ
03/11	Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025	AQ
29/10/25	Kamada to Present at the Stifel 2025 Healthcare Conference	AQ
02/09/25	Kamada to Participate in Upcoming September Investor Conferences	AQ
13/08/25	Kamada: Q2 Earnings Snapshot	AQ
13/08/25	Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance	AQ